I smarter lol.. $11s Form RW - Registration Withdrawal Request
Recent FBLG News
- FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity • GlobeNewswire Inc. • 04/10/2026 12:30:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/09/2026 09:20:28 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/09/2026 08:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 08:15:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:03:57 PM
- FibroBiologics Announces Closing of $3 Million Public Offering • GlobeNewswire Inc. • 04/02/2026 08:01:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/01/2026 08:19:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/01/2026 04:15:18 AM
- FibroBiologics Announces Pricing of $3 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:00:00 AM
- FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial • GlobeNewswire Inc. • 03/31/2026 08:15:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:19:23 PM
- FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement • GlobeNewswire Inc. • 03/25/2026 08:30:00 PM
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed • GlobeNewswire Inc. • 03/18/2026 03:30:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/13/2026 08:20:53 PM
- FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology • GlobeNewswire Inc. • 03/12/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:03:48 PM
- FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:00:15 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (Canada) • 03/03/2026 03:02:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (US) • 03/03/2026 03:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 02:15:05 PM
- FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis • GlobeNewswire Inc. • 03/02/2026 01:30:00 PM
- FibroBiologics to Present at the BIO Investment & Growth Summit • GlobeNewswire Inc. • 02/26/2026 01:30:00 PM
- FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
